Maze Therapeutics
MAZE

Maze Therapeutics (MAZE) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BTIGMaintainedBuy$46.00Aug 12, 2026
Truist SecuritiesMaintainedBuy$64.00 from $68.00Apr 14, 2026
JP MorganMaintainedOverweight$58.00 from $52.00Mar 31, 2026
HC Wainwright & Co.MaintainedBuy$110.00 from $60.00Mar 25, 2026
BTIGMaintainedBuy$46.00Mar 25, 2026
Truist SecuritiesInitiated CoverageBuy$68.00Mar 18, 2026
WedbushMaintainedOutperform$58.00 from $43.00Mar 16, 2026
MizuhoInitiated CoverageOutperform$97.00Mar 10, 2026
BTIGMaintainedBuy$46.00Mar 9, 2026
GuggenheimMaintainedBuy$58.00 from $46.00Mar 4, 2026
BTIGMaintainedBuy$46.00 from $37.00Jan 16, 2026
Wells FargoInitiated CoverageOverweight$55.00Dec 4, 2025
HC Wainwright & Co.MaintainedBuy$60.00 from $50.00Dec 3, 2025
WedbushMaintainedOutperform$36.00 from $35.00Nov 7, 2025
JP MorganMaintainedOverweight$37.00 from $27.00Sep 29, 2025
HC Wainwright & Co.MaintainedBuy$50.00Sep 18, 2025
GuggenheimMaintainedBuy$34.00 from $19.00Sep 15, 2025
BTIGMaintainedBuy$37.00 from $30.00Sep 12, 2025
HC Wainwright & Co.MaintainedBuy$50.00 from $34.00Sep 12, 2025
BTIGMaintainedBuy$37.00 from $30.00Sep 11, 2025

Frequently asked questions

  • What is the latest analyst rating on MAZE?

    On Aug 12, 2026, BTIG maintained Maze Therapeutics at Buy with a price target of $46.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.